Camel-IDS NV logo

Camel-IDS NV

Camel-IDS NV (spin-off from Vrije Universiteit Brussel) is a early stage biotech company focusing on the development of a novel class of radiopharmaceuticals to fight cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.camel-ids.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Burgemeester Etienne Demunterlaan 1B-1090
Brussels
Belgium
Email
Contact Number
+32 2 479 93 60

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/camel-ids” connections=”true” suffix=””]

Camel-IDS is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies (Camelids), coupled with a therapeutic radioisotope. Camelids are used to transport the radioisotope to selected cancer receptors on the cancer cell surface and will selectively kill cancer cells by irradiation.

Camel-IDS has received seed funding from the Fournier-Majoie Foundation and three business angels, complemented with non-dilutive funding from Innoviris.